News - Concomitant drugs
2009-01-13 17:00:00
-Growing Body of Data Supports XELOX as Effective Alternative to Standard of Care- NUTLEY, N.J., Jan.
2007-03-30 09:00:12
NUTLEY, N.J., March 26 /PRNewswire-FirstCall/ -- Roche announced today the submission of a supplemental new drug application (sNDA) to the U.S.
2006-12-11 03:00:09
NUTLEY, N.J., Dec. 11 /PRNewswire/ -- Roche announced today that a large, international Phase III study (NO16967) of 627 previously treated patients with advanced colorectal cancer met its primary endpoint of progression-free survival.
2006-07-31 03:00:11
NUTLEY, N.J., July 31 /PRNewswire/ -- Roche announced today that a large, international Phase III study (NO16966) enrolling 2,035 previously untreated metastatic colorectal cancer patients met both primary endpoints.